Welcome to our dedicated page for Amarin Plc news (Ticker: AMRN), a resource for investors and traders seeking the latest updates and insights on Amarin Plc stock.
Amarin Corporation Plc (NASDAQ: AMRN) is a pioneering biopharmaceutical company dedicated to improving cardiovascular health through the development and commercialization of innovative therapeutic products. The company's flagship product, VASCEPA® (icosapent ethyl), is designed to address cardiovascular risks and has received FDA approval in the United States as well as marketing authorization in Europe under the brand name VAZKEPA®.
Amarin's mission is to advance scientific understanding and provide effective treatments for high-risk cardiovascular patients who have not adequately responded to traditional therapies. VASCEPA, a unique form of eicosapentaenoic acid (EPA), has been shown in clinical trials to significantly reduce cardiovascular events, offering a new therapeutic option for patients with elevated triglyceride levels.
In recent years, Amarin has undertaken strategic initiatives to bolster its market presence and financial stability. Notable accomplishments include:
- Leadership Restructure: In 2023, Amarin appointed new executives, including President & CEO Patrick Holt, to drive the company's global strategy and operational improvements.
- Revenue Growth in Europe: Amarin reported approximately 65% growth in in-market sales in Europe for Q1 2024 compared to Q4 2023, with significant progress in Spain and the UK.
- Financial Discipline: The company has implemented measures to reduce operating expenses and preserve cash, closing 2023 with $321 million in cash and no debt.
- Share Repurchase Plan: In early 2024, Amarin announced a share repurchase plan of up to $50 million to enhance shareholder value, pending necessary approvals.
Amarin's commitment to cardiovascular health extends globally, with operations in the United States, Europe, and partnerships in Canada, China, and other regions. The company continues to explore new market opportunities and strengthen its intellectual property portfolio, as evidenced by the recent extension of VAZKEPA's patent protection in Europe until 2039.
For more information, visit www.amarincorp.com and the dedicated VASCEPA site at www.vascepa.com.
Amarin Corporation plc (NASDAQ:AMRN) has appointed Dr. Murray W. Stewart to its Board of Directors, following a significant board refreshment initiative that has resulted in around 70% new independent directors within the past year. Dr. Stewart brings over 30 years of cardiometabolic academic and industry experience, including roles at GlaxoSmithKline and Rhythm Pharmaceuticals. His appointment aligns with Amarin's strategy to expand into Europe and diversify its product portfolio, enhancing its focus on global, cardiometabolic health.
Amarin Corporation plc (NASDAQ:AMRN) announced that CEO Karim Mikhail will speak at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 8:15 p.m. ET. This event occurs from January 9-12, 2023, in San Francisco, California. The presentation will be webcast live and available for later viewing on Amarin's Investor Relations webpage.
Amarin focuses on cardiovascular disease management, emphasizing scientific research and clinical trials as it expands its commercial presence.
Amarin Corporation plc (NASDAQ:AMRN) announced the approval of its drug VAZKEPA (icosapent ethyl) by Switzerland's Swissmedic. The drug is indicated for reducing cardiovascular risks in high-risk adults. This marks the sixth approval of the VAZKEPA franchise in 2022. Amarin is concurrently pursuing national pricing and reimbursement, expected to complete in 2023. The approval supports Amarin's strategy to strengthen its European operations, having established a regional hub in Zug, Switzerland, in 2021, which hosts over 30 employees dedicated to commercial and medical roles.
Amarin Corporation announced that Australia's Therapeutic Goods Administration (TGA) has approved VAZKEPA (icosapent ethyl) for reducing the risk of cardiovascular (CV) events in adult statin-treated patients with high CV risk and elevated triglycerides. This marks the fifth regulatory approval for the VAZKEPA franchise in key international markets in 2022. The company will initiate the reimbursement process to support commercialization in Australia, backed by patents providing market exclusivity into the early 2030s.
Amarin Corporation (NASDAQ:AMRN) announced that CEO Karim Mikhail will participate in the Jefferies London Healthcare Conference from November 15-17, 2022. Mikhail's presentation is scheduled for November 16, 2022, at 9:40 a.m. ET (2:40 p.m. GMT+1).
This event will be webcast live, with an archived version available on Amarin's Investor Relations website. The company focuses on advancing cardiovascular disease management through scientific research and clinical trials.
Amarin Corporation presents key findings from the RESPECT-EPA study at the AHA 2022 Scientific Sessions, highlighting the cardiovascular risk reduction benefits of eicosapentaenoic acid (EPA) for patients with coronary artery disease (CAD). The study demonstrated a 21.5% reduction in cardiovascular risk (p=0.054) and a 26.6% reduction in a secondary endpoint (p=0.03). In contrast, the PROMINENT study reported no cardiovascular benefits from the fibrate class for high-risk patients. The results reinforce the therapeutic value of VASCEPA/VAZKEPA in managing cardiovascular risk alongside statin therapy.
Amarin Corporation (NASDAQ:AMRN) announced Q3 2022 financial results, reporting a net revenue of $89.9 million, down 37% from Q3 2021, largely due to increasing generic competition affecting VASCEPA sales. The company secured positive reimbursement assessments in several European markets, including Finland and the Netherlands, and launched VAZKEPA in the UK. Efforts to stabilize US revenues continued, achieving a cash-positive quarter excluding restructuring charges. Amarin's cost-saving measures are projected to yield $100 million by mid-2023, extending its cash runway amid ongoing market access negotiations.
Amarin Corporation plc (NASDAQ:AMRN) has announced the retirement of Lars Ekman and Patrick O’Sullivan from its Board of Directors effective year-end, following a significant refreshment program. Adam Berger and Geraldine Murphy are appointed as new independent directors, contributing extensive international experience in healthcare and finance. With 75% of the board refreshed over the past year, the company aims to enhance its expertise to support global expansion and strategic objectives. This leadership change is designed to align with Amarin's mission to advance cardiovascular disease management.
Amarin Corporation plc (NASDAQ:AMRN) will host a conference call on October 27, 2022, at 8:00 a.m. ET to discuss its third quarter 2022 financial results. The call follows the pre-market release of the financial results. Interested parties can access the live call through the investor relations section of Amarin's website or via dial-in options provided for both U.S. and international participants. A replay of the call will also be available after the event through the website.
Amarin Corporation plc (NASDAQ:AMRN) announced significant changes in its Board of Directors, emphasizing an active board refreshment process. The board supports a new strategic direction aimed at expanding its business in Europe and enhancing U.S. operations. In 2022, three independent directors with extensive biotech and pharmaceutical experience were appointed. The board is in the final stages of appointing new directors and remains committed to constructive engagement with shareholders, including Sarissa Capital Management.
FAQ
What is the current stock price of Amarin Plc (AMRN)?
What is the market cap of Amarin Plc (AMRN)?
What does Amarin Corporation do?
What is VASCEPA®?
How did Amarin perform financially in recent quarters?
What recent strategic initiatives has Amarin undertaken?
What are the key markets for Amarin's products?
What recent achievements have boosted Amarin's market position?
How does VASCEPA® benefit patients?
Who are the key executives at Amarin?
What is the purpose of Amarin's share repurchase plan?